Key Takeaways CHMP recommends updating Ozempic's EU label based on positive STRIDE PAD outcomes in T2D patients. Ozempic showed improved walking capacity in patients with T2D and PAD in the late-stage STRIDE study. NVO expects EC approval of the PAD label update within two months; FDA review is underway in the U.S.Novo Nordisk (NVO) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending that Ozempic’s (once-weekly se ...